The North America Laboratory Centrifuges Market was valued at USD 1,350 Million in 2025 and is projected to reach USD 2,250 Million by 2035, expanding at a CAGR of 4.6% during the forecast period 2024 to 2035. The market is driven by increasing investments in research and diagnostics, and a strong presence of leading manufacturers and research institutes in the region.
The economic impact of tariffs on "North America Laboratory Centrifuges Market".
Market Growth Drivers
Rising Prevalence of Chronic Diseases: The surge in chronic diseases such as cancer and cardiovascular disorders in North America has fueled demand for laboratory diagnostics, thereby boosting the adoption of centrifuges. For example, Thermo Fisher Scientific has escalated its centrifuge production capacity to meet the increasing requirement for sample preparation in disease diagnostics.
Advancements in Genomics and Proteomics: The growing emphasis on personalized medicine and molecular biology requires high-precision equipment for cellular and molecular analyses. Companies like Beckman Coulter are innovating their centrifuge lines to deliver enhanced speed and efficiency, supporting advanced research in genomics and proteomics.
Market Trends
Rapid Adoption of Automation: Laboratories are increasingly incorporating automation and smart technologies into their workflow, enabling higher throughput and consistency. Eppendorf North America, for instance, introduced new models equipped with digital interfaces and programmable settings, allowing seamless integration into automated lab environments.
Sustainable and Energy-Efficient Designs: Environmental regulations and operational cost control are pressing laboratories to shift toward centrifuges with improved energy efficiency. Companies such as Hettich have developed centrifuges focused on reducing power consumption and minimizing noise, to align with sustainability mandates and work safety standards.
Market Opportunities
Expanding Biopharmaceutical Sector: The rise of contract research organizations and biopharmacological innovations across North America presents significant opportunities for centrifuge manufacturers such as Thermo Fisher Scientific to supply products tailored for bioprocessing applications.
Growth in Point-of-Care Testing: The increasing focus on decentralized diagnostics and rapid point-of-care testing, spearheaded by companies such as Danaher Corporation, creates avenues for compact and portable centrifuge solutions.
North America Laboratory Centrifuges Market Revenue (USD Million), 2020–2035
The market revenue chart demonstrates consistent growth in the North America Laboratory Centrifuges Market from 2020 through 2035. Starting at USD 1,000 Million in 2020, the market observed a steady increase, reaching USD 1,350 Million by 2025. This upward trajectory reflects robust investments in the life sciences domain and the growing adoption of laboratory automation. Key contributors include rising R&D in biopharma and greater healthcare expenditure across the region. By 2035, the market is projected to hit USD 2,250 Million, signifying a positive outlook for stakeholders and suppliers in the clinical and research laboratory industry.
North America Laboratory Centrifuges Market Share by Region, 2025
The 2025 regional market share pie chart indicates the dominance of the United States in the North America Laboratory Centrifuges Market, comprising 76% of the market. Canada follows with 16% share, supported by continued investments in research infrastructure. Mexico accounts for 5%, driven by growing healthcare development. Minor shares are held by Puerto Rico (2%) and other North American territories (1%). This spread emphasizes the key role of U.S.-based academic institutions and clinical labs, while also marking the growing prominence of Canada and Mexico as emerging hubs for laboratory technology.
Recent Developments
In May 2024, Thermo Fisher Scientific announced the launch of a high-capacity floor-standing centrifuge, the Sorvall LYNX 1200, which extends application options and provides improved safety features and digital traceability. The product is aimed at supporting biopharmaceutical research and cell therapy manufacturing.
Eppendorf North America unveiled an upgraded version of their 5910Ri centrifuge in March 2024, featuring an advanced touchscreen interface and cloud-based monitoring. This move reflects the push towards digital transformation in laboratory processing, improving operational efficiency across North American labs.
Beckman Coulter Life Sciences entered into a strategic partnership in February 2024 with a large Canadian research consortium to provide benchtop and microcentrifuge equipment for genomics and proteomics studies, strengthening their regional presence and accelerating research outputs.
Press Releases